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Cardiac troponin I (cTnI) is an important regulatory protein in cardiac muscle, and its
modification represents a key mechanism in the regulation of cardiac muscle contraction and
relaxation. cTnI is often referred to as the “gold-standard” serum biomarker for diagnosing
patients with acute cardiac injury since it is unique to the heart and released into the circulation
following necrotic death of cardiac tissue. The swine (Sus scrofa) heart model is extremely
valuable for cardiovascular research since the heart anatomy and coronary artery distribution
of swine are almost identical to those of humans. Herein, we report a comprehensive
characterization of the modifications in swine cTnI using top-down high-resolution tandem
mass spectrometry in conjugation with immunoaffinity chromatography purification. High-
resolution high accuracy mass spectrometry revealed that swine cTnI affinity purified from
domestic pig hearts was N-terminally acetylated and phosphorylated. Electron capture
disassociation is uniquely suited for localization of labile phosphorylations, which unambig-
uously identified Ser22/Ser23 as the only basally phosphorylated sites that are well-known to
be regulated by protein kinase A and protein kinase C. Moreover, a combination of tandem
mass spectrometry with sequence homology alignment effectively localized a single amino
acid polymorphism, V116A, representing a novel genetic variant of swine cTnI. Overall, our
studies demonstrated the unique power of top-down high-resolution tandem mass spectrom-
etry in the characterization of protein modifications, including labile phosphorylation and
unexpected sequence variants. (J Am Soc Mass Spectrom 2010, 21, 940–948) © 2010 American
Society for Mass SpectrometryCardiac troponin I (cTnI) is an important regula-tory protein in the cardiac muscle. Its interactionwith tropomyosin (Tm) and other binding part-
ners within the troponin protein complex represents a
key mechanism in the regulation of cardiac muscle
contraction and relaxation [1, 2]. cTnI is often referred to
as the ”gold-standard” serum biomarker for diagnosing
patients with acute cardiac injury since it is uniquely
present in the heart and released into the general
circulation following necrotic death of heart muscle
tissue [3]. As the inhibitory subunit of the troponin
protein complex, cTnI binds tightly to actin-Tm in the
absence of Ca2 and therefore inhibits the binding of
myosin crossbridges to actin. Modification of cTnI
changes the conformation of the protein and thereby
switches on and off the binding positions on the Tm-
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doi:10.1016/j.jasms.2010.02.005actin complex to modulate muscle contraction and
relaxation. It has been shown that altered modifications
of cTnI are directly linked to cardiac dysfunctions in
various human heart diseases [4]. Altered phosphory-
lation of cTnI may contribute causally to cardiac dys-
function in the transition from compensated hypertro-
phy to heart failure [5, 6]. Proteolytic cleavages of cTnI
have been correlated with myocardial stunning and
ischemia/reperfusion injury [7]. Mutations in the cTnI
gene (TNNI3) have been identified in human familial
hypertrophic cardiomyopathies (HCM) [8] and dilated
cardiomyopathies (DCM) [9].
The domestic pig (Sus scrofa) is an established mam-
malian animal model for human diseases [10–14]. Its
heart anatomy and coronary artery distribution are
almost identical to those of humans [15], making it an
extremely valuable animal model for cardiovascular
research [13, 14]. Furthermore, the myofilament protein
make-up of domestic pig heart shows greater similarity
to humans than rodents, implying a highly analogous
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known to have very high genetic variability and com-
plexity [17, 18], which makes it challenging to use as a
research model. A full-characterization of cardiac
regulatory proteins such as swine cTnI and its mod-
ifications are essential for understanding its role in
cardiac function and thereby establishing proper swine
heart models.
The top-down mass spectrometry (MS) methodol-
ogies [19–33] have unique advantages in assessing
protein modifications, including post-translational
modifications (PTMs) and sequence variants. In the
conventional bottom-up MS approach, proteins are
digested into many small peptides for MS analysis,
resulting in partial sequence coverage and loss of con-
nections between disparate portions of proteins con-
taining modifications [34]. Top-down MS approach
directly analyzes intact proteins, providing a “bird’s
eye” view of the protein and reveals all possible mod-
ifications present in vivo without a priori knowledge
[35, 36]. Individual protein modifications are then iso-
lated in the gas phase and directly subjected to tandem
mass spectrometry (MS/MS) analysis for detailed struc-
tural characterization, thus allowing a highly reliable
mapping of the modification sites with full sequence
coverage [28, 29, 37]. In addition, it greatly simplifies
sample preparation and reduces sample complexity as
no proteolytic digestion is required. Top-down MS is
considerably enhanced with multiple MS/MS fragmenta-
tion techniques, including electron capture dissociation
(ECD) [38], collisionally activated dissociation (CAD) [39],
and infrared multiphoton dissociation (IRMPD) [40] to
provide complementary information for comprehensive
protein structural characterization. Top-down MS with
ECD becomes an extremely valuable tool in mapping
labile protein modifications [21, 41], most notably phos-
phorylation [28–30, 42].
Herein, we have employed an integrated top-down
MS strategy combining affinity chromatography for
effective purification of cTn from left ventricles of swine
myocardium and top-down high-resolution MS/MS for
comprehensive analysis of swine cTnI and its modifica-
tions. We have thoroughly characterized all the modi-
fications of swine cTnI present in vivo, localized the
acetylation and phosphorylation sites, and discovered a
novel single amino acid polymorphism that represents
a new genetic variant of swine cTnI.
Experimental
Chemicals and Reagents
All reagents were purchased from Sigma Chemcial
Co. (St. Louis, MO, USA) unless noted otherwise.
Complete protease and phosphatase inhibitor cock-
tail tablets were purchased from Roche Diagnostics
Corp. (Indianapolis, IN, USA). All solutions were
prepared in Milli-Q water (Millipore Corp., Billerica,
MA, USA).Immunoaffinity Purification of Swine cTn
Swine heart tissues were obtained from juvenile York-
shire domestic pig as approved by the University of
Wisconsin Animal Care and Use Committee. The ex-
cised heart tissue was immediately frozen in liquid
nitrogen and stored in a 80 °C freezer. The whole
cardiac troponin complex was purified by the immuno-
affinity purification method as previously described
[29]. Briefly, 1.5 g of heart tissue was homogenized in
tissue wash buffer (NaH2PO4 500 mM, Na2HPO4 100
mM, MgCl2 100 mM, EGTA 100 mM, NaCl 0.1 M, Triton
X-100 1%, DTT 5 mM, protease and phosphatase inhib-
itor cocktail tablet, PMSF 1 mM, leupeptin 2 g/mL, pH
7.4) using a Polytron electric homogenizer (Model
PRO200, PRO Scientific Inc., Oxford, CT, USA) for 30 s
on ice. The homogenate was centrifuged at 8000 rpm for
10 min at 4 °C; the supernatant was discarded and the
pellet was resuspended in 6 mL protein extraction
buffer (0.7 M LiCl, 25 mM Tris, 5 mM EGTA, 0.1 mM
CaCl2, 5 mM DTT, 1 mM PMSF, 2 g/mL leupeptin,
and 0.75 mg/mL protease and phosphatase inhibitor
cocktail, pH 8.0) and protein extraction was performed
with agitation on a nutating mixer (Fisher Scientific Inc.,
Pittsburgh, PA, USA) at 4 °C for 45 min. The sample
was then centrifuged at 16,000 rpm (Centrifuge 5415R;
Eppendorf, Hamburg, Germany) for 5 min to collect the
supernatant. The collected supernatant was further cen-
trifuged at 55,000 rpm (Beckman L-55 ultracentrifuge;
Beckman Coulter, Fullerton, CA, USA) for 45 min to
completely remove the tissue debris before affinity
chromatography purification. The supernatant was in-
cubated with 0.25 mL of CNBr-activated Sepharose
CL-4B conjugated with 1.25 mg monoclonal cTnI anti-
body (anti-troponin I monoclonal antibody MF4 and
14G5; HyTest Ltd., Turku, Finland) for 35 min at 4 °C to
ensure complete binding of troponin complex to the
antibody. After washing the column with 2 mL of
extraction buffer, the bound troponin complex was
eluted with 100 mM glycine at pH 2 into four 0.4 mL
fractions and neutralized immediately with 40 L of 1M
MOPS (pH 9). Fractions were analyzed for enriched
protein content by 15% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) gels stained
with Coomassie blue. Typically, 200 g of cTnI was
recovered from each affinity purification experiment.
Analytical repeatability and reproducibility were as-
sessed with three technical replicates (independent pu-
rification experiments) for two biological replicates.
Top-Down Mass Spectrometry of Swine cTnI
Immunoaffinity purified swine cTn complexes were
separated and desalted using an offline reverse phase
protein microtrap (Michrom Bioresources, Inc., CA,
USA), with a two step reverse phase gradient elution
method, first with 1% acetic acid in 30:70 methanol/
water and then 1% acetic acid in 75:25 methanol/water.
Desalted samples were analyzed using a 7T linear
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(Thermo Scientific Inc., Bremen, Germany) equipped
with an automated chip-based nano ESI source (Triv-
ersa NanoMate; Advion BioSciences, Ithaca, NY, USA).
The spray voltage was 1.2–1.6 kV versus the inlet of the
mass spectrometer, resulting in a flow of 50–200 nL/
min. Ion transmission into the linear trap and subse-
quently into the FTICR cell was automatically opti-
mized for maximum ion signal. The number of
accumulated ions for the full scan linear trap (IT),
FTICR cell (FT), MSn FTICR cell, and ECD were 3 104,
8 106, 8 106, and 8 106, respectively. The resolving
power of the FTICR mass analyzer was typically set at
200,000 at m/z 400, resulting in an acquisition rate of 1
scan/s. For CAD and ECD fragmentation, individual
charge states of protein molecular ions were first iso-
lated and then dissociated using 10%–25% normalized
collision energy (CAD) or 2%–3% electron energy
(ECD) with a 45–125 ms duration with no delay. Typi-
cally, 1000 to 3000 transients were averaged to ensure
high quality ECD spectra.
All FTICR spectra were processed with Xtract Soft-
ware (FT programs 2.0.1.0.6.1.4, Xcalibur 2.0.5, Thermo
Scientific Inc., Bremen, Germany) using S/N threshold
of 1.5 and fit factor of 40% and validated manually. The
resulting mass lists were further assigned using in-
house developed “Ion Assignment” software (version
1.0) based on the protein sequence of swine cTnI
obtained from Swiss-Prot protein knowledgebase (Unit-
ProtKB/Swiss-Prot). Allowance was made for possible
PTMs such as the removal of initial Met, acetylation of
the N-terminus, and variable phosphorylation sites
(residues Ser, Thr, and Tyr), using a 10 and 20 ppm
tolerance for precursor and fragment ions, respectively.
The assigned ions were manually validated to ensure
the quality of assignments. For fragment ions contain-
ing possible phosphorylation sites, the mass of frag-
ment ions were manually examined for 80 Da mass
shifts to confirm or exclude the existence of phosphor-
ylation. All reported masses are the most abundant
masses. The MS signal intensity values were used to
calculate the relative ratios for all the observed protein
ions based on a method developed by Kelleher and
coworkers known as the protein ion relative ratio
(PIRR) [43] with modifications [29, 30]. The top five
most abundant isotopomer peak heights were inte-
grated to calculate the relative abundance of the intact
protein or fragmentation ions.
Results and Discussion
High-Resolution Mass Spectrometry Analysis of
Swine cTnI
The SDS-PAGE analysis of the immunoaffinity purified
proteins revealed three major bands (Supplemental
Figure 1, which can be found in the electronic version of
this article) representing the three subunits of cTn
protein complex, cTnC, cTnI, and cTnT, respectively.The cTn subunits were further separated and desalted
via an offline reverse phase HPLC using a two step
gradient elution method and subjected to high-
resolution FTMS analysis. Figure 1a shows the broad-
band FTMS spectrum of swine cTnI fraction in 75:25
methanol:water with 1% acetic acid. High-resolution
FTMS analysis of swine cTnI fractions revealed the
presence of three major molecular weights (23,951.76,
Figure 1. High-resolution MS analysis of intact cTnI purified
from domestic pig hearts. (a) Broadband ESI/FTMS spectrum of
desalted swine cTnI sample. (b) Expanded MS spectrum of swine
cTnI from m/z 818 to 868. (c) Narrow band FTMS spectrum of
swine cTnI for the charge state 28 precursor ions, showing its
distribution in un-, mono-, and bisphosphorylated forms. Insets:
isotopically resolved molecular ions of un-, mono-, and bisphos-
phorylated cTnI (M28) with high accuracy molecular weight
measurements. pcTnI and ppcTnI represent mono- (79.95 Da)
and bisphosphorylated (159.92 Da) cTnI, respectively. Dashed
arrow indicates the expected position for trisphosphorylated
cTnI (pppcTnI), which is not observed here. Circles represent the
theoretical isotopic abundance distribution of the isotopomer
peaks corresponding to the assigned mass. Calc’d: calculated
most abundant mass; Expt’l: experimental most abundant mass.
H3PO4: noncovalent adduct of phosphoric acid (98 Da).
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of 79.96 Da suggesting phosphorylation of swine cTnI
(Figure 1b, c). However, none of the observed molecular
weights matched with the two widely reported swine
cTnI sequences in UniProtKB/SwissProt protein database
(http://www.uniprot.org/uniprot/), A5X5T5_PIG and
A5X497_PIG from gene TNNI3 (Figure 2, top two
sequences, 211 amino acid residues, 24,068.81 Da and
23,982.48 Da, respectively), even with consideration of
common PTMs such as possible deletion of initiating
Met and acetylation. So we applied both ECD and CAD
to individually isolated precursor ions of 23,951.76 Da,
presumably the unphosphorylated cTnI form, to iden-
tify the correct sequence. The detected product ions
were assigned with these two reported swine cTnI
sequences that differ in three residues S42/P42, R74/
S74, and V116/A116 (Supplemental Figure 2). For both
sequences, the product ions gave identical assignments
in the N-terminus before S42/P42. After S42, the de-
tected product ions continued to assign larger c and b
ions based on the sequence A5X5T5_pig, including c42,
c45, c47, c48, c49, c50, c51, c53, c54, c55, c58, c59, c60, c63, c65, c67,
c70, c71, c74, and b53, b54, b58, b66, b84, b85, b86, b87, b89, b115,
while these matches were absent for the sequence
A5X497_pig (Supplemental Figure 2). ECD spectrum of
23,951.76 Da matched extensively with A5X5T5_PIG,
after deletion of N-terminal Met and incorporation of
acetylation at the new N-terminus (Supplemental Fig-
ure 3). Overall, the MS/MS data suggested that se-
quence of A5X5T5_PIG is the better match for the swine
cTnI analyzed here rather than A5X497_pig. The other
two molecular masses, 24,031.75 Da and 24,111.71 Da,
were assigned as monophosphorylated and bisphos-
phorylated cTnI, respectively, based on highly accurate
molecular mass measurements (Figure 1c insets). Nev-
ertheless, the high accuracy mass measurements of the
three major cTnI forms (Figure 1c) clearly showed a
mass discrepancy (28 Da) between the experimental
and calculated masses of swine cTnI (A5X5T5_PIG)
Figure 2. Partial sequence alignment of cTnI from several mam-
malian species using a Clustal (2.0.11) algorithm. Sequences were
downloaded from UnitProtKB/Swiss-Prot. Two splicing isoforms
of pig cTnI sequences were aligned with cTnI sequences of bovine,
human, mouse, and rat. Numerals indicating amino acid positions
are according to the full sequence with the initiating N-terminal
Met. Amino acid differences between two swine cTnI isoforms
were highlighted in rectangles.with consideration of acetylation and phosphorylation.As shown in Figure 1b, only minor degradation prod-
ucts of cTnI assigned as P[33-210]G and Y[26-210]G
were observed in this sample, indicating the heart
samples were well-preserved during the storage and
purification procedures.
Localization of Phosphorylation Sites in Swine cTnI
The relative intensity ratio for cTnI in its unphos-
phorylated (cTnI), monophosphorylated (pcTnI), and
bisphosphorylated (ppcTnI) forms was 6.8%  1.3%
27.8%  1.4%, and 64%  2.7%, respectively, indicating
that swine cTnI was predominantly basally phosphor-
ylated. No trisphosphorylated cTnI was detected, im-
plying higher order phosphorylation was not present in
the swine cTnI sample analyzed, or below the detection
limit of the FTMS method used in this study (estimated
to be 1% of the total cTnI protein population based on
the signal intensity at the expected position of trisphos-
phorylated cTnI over the summed intensity of all cTnI
forms).
To determine the phosphorylation sites, the precur-
sor ions of bisphosphorylated cTnI were isolated and
fragmented by both ECD and CAD. One ECD spectrum
generated 175 validated high quality MS/MS peaks
(Figure 3). No phosphorylated product ions were de-
tected for c19, c20, and c21, as well as other smaller c ions,
which provided unambiguous evidence that the first 21
Figure 3. ECD spectrum of isolated bisphosphorylated cTnI
(ppcTnI). The product ion assignments were made according to the
sequence A5X5T5_PIG with the removal of N-terminal Met and
acetylation at the new terminus.
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sites (Figure 4a, b, c). In contrast, monophosphorylated
c22 ions (pc22) was detected, which clearly indicated the
phosphorylation of Ser22 (Figure 4d). No unphosphor-
ylated c22 was detected (estimated to be 4% of the
monophosphorylated c22 ions), which suggested Ser22
was completely phosphorylated and confirmed there
was no phosphoryl group loss during ECD fragmenta-
tion. Similarly, bisphosphorylated c23 ions (ppc23) were
also detected, indicating the successive phosphoryla-
tion on Ser23 (Figure 4e). No unphosphorylated or
monophosphorylated counter ions were detected for
ppc23 and ppc27 (estimated to be 2%–3% of the bisphos-
phorylated c23 and c27 ions), which revealed the full
phosphorylation occupancy on Ser22 and Ser23 (Figure
4e, f). Conversely, if other phosphorylation sites exist in
the bisphosphorylated cTnI, one would expect to ob-
Figure 4. Key product ions (a–f) from the ECD spectra for
localization of swine cTnI bisphosphorylation sites. Solid arrows
indicate the observed product ions; dashed arrows indicate the
absence of the labeled product ions. Circles represent the theoret-
ical isotopic abundance distribution of the isotopomer peaks
corresponding to the assigned mass. c and c stand for mono-p pp
and bisphosphorylated c ions.serve un- and monophosphorylated c22, c23, and c27 ions,
which were not observed in our experiments.
The identification of Ser22/23 as the only phosphor-
ylation sites is consistent with our previous report on a
mouse cTnI [29]. Phosphorylation of Ser22/23 are well-
known to be regulated by protein kinase A (PKA) upon
-adrenergic stimulation [44]. Protein kinase C (PKC,
// isozymes) can cross-phosphorylate the PKA sites
of cTnI at Ser22/23 as well as protein kinase D (PKD)
and cyclic GMP-dependent protein kinase (PKG) [45–
47] [6]. Our previously reported human cTnI study also
revealed that Ser22/23 are the two basally phosphory-
lated sites [28]. The cTnI sequences of these closely
related mammalian species also showed striking simi-
larities (Figure 2), with a 93% sequence homology
between mouse, pig, and human. The sequence similar-
ity is even higher between close members within the
same family, such as mouse and rat (99% sequence
homology). The conservation of cTnI basal phosphory-
lation sites within multiple mammalian species implies
a highly analogous functional role of cTnI in regulating
cardiac contraction and relaxation.
The phosphorylation of cTnI has been well-studied
and demonstrated to be essential for modulating car-
diac function [2, 4–6]. Apart from the Ser22/23 (known
as Ser23/24 considering the N-terminal Met) phosphor-
ylation sites as identified here, there is a significant
body of literature demonstrating the phosphorylation
sites at Ser42/44 and Thr143 (Ser43/45 and Thr144 with
the N-terminal Met) [2, 6, 45–49]. However, these other
phosphorylation sites (Ser42/44 and Thr143) were iden-
tified from in vitro phosphorylation assays. In contrast,
the sites identified in this study (Ser22/23) are basally
presented in swine cTnI in vivo. Ser22/23 are also the
only sites basally phosphorylated in wild-type healthy
mice, which has been systematically investigated in our
previous publication [29]. The observation of basal
phosphorylation sites at Ser22/23 does not lessen the
significance of the PKC phosphorylation as discussed
previously [29]. Ser42/44 and Thr143 are the substrates
for protein kinase C (PKC) [2, 6, 45–49] and PKC was
shown to be up-regulated in the end stage heart failure
[50]. Thus, it is reasonable to suspect that these PKC
sites may be considered maladaptive and connected
with disorders of the heart [2]. A heart at the end stage
failure is substantially different from a healthy one at
the molecular and cellular level [49]. Please note that the
cTnI analyzed here is from healthy pig hearts, so their
phosphorylation state could be different from those of
diseased hearts. Another possibility is that the PKC sites
may present in extremely low phosphorylation occu-
pancy in cTnI that are too low to be detected. Since
every analytical method has its own detection limit, we
cannot exclude the possibility of other sites of very low
(1%) phosphorylation occupancy.
To address the concern whether affinity purification
may selectively enrich certain types of phosphorylated
species, we have used antibodies of different epitope
regions (N-terminal residues 1–23 versus C-terminal
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showed the same cTnI species were detected regardless
of the antibodies used (data not shown). Hence, this
suggests that the overall impact of affinity chromatog-
raphy on the phosphoprotein selection was minimal.
Localization of Single Amino Acid Polymorphism
in Swine cTnI
To locate the mass discrepancy of 28 Da, we applied
ECD and CAD directly to the individually isolated un-
and bisphosphorylated cTnI molecular ions, respec-
tively (Figure 5). Both ECD and CAD fragmentation
generated extensive product ions, which matched the
N- and C-terminal ions predicted from the sequence
A5X5T5_pig precisely, indicating the mass discrepancy
site was not near either C- or N-termini. The largest
fragmentation ions detected in ECD spectra of unphos-
phorylated (Figure 5a) and bisphosphorylated cTnI
(Figure 5b), c74 and z
•
76, c85, and z
•
77, respectively, were
matched with the sequence A5X5T5_pig with high
accuracy. Meanwhile the larger ions observed in ECD of
unphosphorylated cTnI (Figure 5a) including z•103,
Figure 5. MS/MS fragmentation and product
(b) bisphosphorylated swine cTnI (ppcTnI). Fra
(UnitProtKB/Swiss-Prot A5X5T5, TNNI3_pig) w
the new terminus. Bisphosphorylation sites of S
tion ions carrying the mass discrepancy (28
containing the mass discrepancy (28 Da) are highliz•119, z
•
172, z
•
185, z
•
209, and c209 all carry a 28 Da mass
discrepancy, which restricts such a mass discrepancy to
the middle of the sequence D[108-133]F. CADwith mild
fragmentation conditions (10%–15% normalized colli-
sional energy) of the isolated bisphosphorylated cTnI
(ppcTnI) precursor ions produced many larger product
ions (Figure 6) including 18 b/y complementary pairs
with full sequence coverage (Figure 5b). No 28 Da
mass discrepancies were observed in smaller b/y frag-
mentation ion series, b3-b115 and y4-y88. In contrast, all
the larger b/y ions, b122-b198, and y95-y209 contain such a
28 Da mass discrepancy. Hence, the mass discrepancy
site was localized to the seven amino acids between
V116 and I122,VKVTKNI (Figure 5). Taken together,
two ECD and three CAD experiments of the unphos-
phorylated cTnI generated a total of 40 c and 39 z• ions
and 41 b ions and 57 y ions, which unambiguously
localized the acetylation site to the N-terminus. The
overall fragmentation map of the bisphosphorylated
cTnI from two ECD and three CAD experiments gen-
erated a total of 35 c and 41 z• ions corresponding to 76
inter-residue bond cleavages, and 43 b ions and 51 y
ions representing 77 bond cleavages with full sequence
ap from ECD and CAD spectra for (a) un- and
ts assignments were made to the swine cTnI
e removal of N-terminal Met and acetylation at
23 were highlighted by circles. The fragmenta-
s indicated in dots. The potential amino acidsion m
gmen
ith th
er22/
Da) ighted in shades.
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with high mass accuracy with root mean square (RMS)
values of 4.6 and 6.3 ppm for ECD and CAD data,
respectively.
We performed three independent purification exper-
iments for the two biological replicates, which consis-
tently showed the 28 Da mass discrepancy in swine
cTnI (data not shown). The 28 Da mass discrepancy
most likely resulted from an amino acid polymorphism
rather than a PTM since there is no common protein
PTM that corresponds to a 28 Da shift. It is highly
unlikely to be a combination of two or more PTMs
within such a short amino acid sequence range. A 28
Da mass shift could potentially be generated from
amino acid polymorphisms of V/A, D/S, E/T, M/C,
and R/K (Table 1). So the only possibility to account for
28 Da shift in this sequence region, VKVTKNI, is
either V116A or V118A. Moreover, the sequence align-
ment of cTnI from multiple mammalian species shows
Figure 6. Representative product ions (a–h) from the CAD
spectrum of bisphosphorylated swine cTnI for localization of the
mass discrepancy (28 Da). Product ions are assigned according
to the sequence A5X5T5_pig with the removal of N-terminal Met,
acetylation at the new terminus, and phosphorylations at Ser22
and Ser23. Circles represent the theoretical isotopic abundance
distribution of the isotopomer peaks corresponding to the as-
signed mass. Calc’d: calculated most abundant mass; Expt’l:
experimental most abundant mass.that within the seven amino acids region V116-I122, allother amino acids are conserved except V116 (Figure 2).
Val is only present in swine cTnI (A5X5T5_Pig) whereas
Ala is commonly predicted for amino acid position 116
(117 if including the N-terminal Met) of bovine, human,
mouse, and rat cTnI sequences as well as the other
sequence variant of swine cTnI (AA5X497_Pig). There-
fore, the single amino acid polymorphism in swine cTnI
is most likely at amino acid position 116 (V116A). The
domestic pig is a species known to be of high genetic
variability [17, 18]. However, currently there are only
two reported cTnI sequence variants in the Swiss-Prot
and NCBI database from one common ancestor gene
TNNI3, with three amino acid polymorphism sites in a
total of 211 residues. Hence, the observed cTnI in our
experiments represents a novel sequence variant that is
first reported here.
Top-Down MS/MS for Determination of
Protein Modifications
As demonstrated here, top-down MS methodology of-
fers unique advantages in assessing protein modifica-
tions including PTMs and sequence variants. The MS
acquired at the intact protein level (the “top” part)
provides a “bird’s eye” view of all potential modifica-
tions [26, 35] and the MS/MS of the isolated ions of
interests (the “down” part) reliably localizes the modi-
fication sites. In this study, we have unambiguously
identified two basal phosphorylation sites and one
novel single amino acid polymorphism of swine cTnI.
We found that the two MS/MS techniques, ECD and
CAD, are complementary for characterization of PTMs
and amino acid polymorphisms. ECD is uniquely suit-
able for determination of labile modifications such as
phosphorylation since it preserves labile modifications
during MS/MS process as demonstrated in this study.
Such labile modifications have often been “knocked-
off” in conventional energetic fragmentation process
such as CAD, IRMPD, and post-source decay (PSD). On
the other hand, the efficiency of CAD (70%–80%) is
higher than ECD (10%–30%), which generates more
ions for the reliable identification of stable PTMs sites
and amino acid polymorphisms. Furthermore, it is
more difficult to obtain large fragmentation ions in an
ECD spectrum than CAD. Here we have selected a mild
energy condition for CAD experiments, which gener-
Table 1. Possible amino acid polymorphisms with 28 Da
mass difference
Polymorphism*
Mass difference (Da)
Monoisotopic Average
V/A 28.03 27.99
D/S 28.00 28.02
E/T 27.99 28.00
M/C 28.03 28.10
R/K 28.01 28.00*X/Y stands for the polymorphism of amino acid residue X to Y.
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of a single amino acid polymorphism site that is located
in the middle of the protein sequence.
Top-down MS methodology is superior in resolving
unexpected modifications without a priori knowledge.
Given the highly accurate mass measurement and ex-
tensive product ion matches from both ECD and CAD,
our data revealed a single amino acid polymorphism,
suggesting a novel cTnI sequence variant in the domes-
tic pig. Although bottom-up MS appears to be highly
efficient for sequencing small tryptic peptides and valu-
able for large scale high throughput protein identifica-
tion, it can easily overlook unexpected PTMs or se-
quence variants. In the bottom-up approach, proteins
are digested into smaller tryptic peptides and the MS
analysis is performed at the peptide level. The informa-
tion regarding the whole protein is then pieced together
from its peptide components. Such a bottom-up ap-
proach relies heavily on the presence of the existing
protein sequences in the database and a priori knowl-
edge of expected modifications for identification of
protein sequences and the modification sites. Moreover,
due to the partial sequence coverage, the bottom-up
strategy has a very limited ability to discern proteins
with high sequence similarities, let alone single amino
acid polymorphisms as identified in this study using a
top-down MS approach. In addition, piecing very small
tryptic peptides together often results in the loss of
connections between disparate portions of proteins con-
taining modifications, thereby limiting the ability for
detailed protein structural characterization. On the con-
trary, in the top-down MS approach, all PTMs and
sequence variations can be resolved at the molecular
ion level without a priori knowledge [26]. MS/MS
fragmentation is directly performed at the intact protein
level, ensuring full protein sequence coverage for reli-
able mapping of PTMs [37] and amino acid polymor-
phisms (also referred to as “protein-sequence polymor-
phisms”) [27, 51]. The ionization efficiency of intact
proteins is much less affected by the presence of a
modifying group in comparison to peptides, thus
making top-down MS especially attractive for quan-
tifying modified positional isomers [28, 43] and ex-
ploring interdependency among multiple modifica-
tion sites [29, 30].
Conclusions
An integrated top-down protein MS strategy combining
immuno-affinity chromatography and high-resolution
FTMS/MS was employed here to study the modifica-
tion state of swine cTnI purified from domestic pig
heart tissues. We have comprehensively characterized
all the modifications in swine cTnI, including acetyla-
tion, phosphorylation, and sequence variants. The high-
resolution MS and MS/MS data from the top-down
experiments provide solid and unbiased evidence re-
garding the possible modification sites in the protein
sequence as exemplified in this study. Top-down ECDunambiguously identified two basal phosphorylation
sites in swine cTnI, which are well conserved among the
mammalian species. A combination of ECD and CAD
with sequence homology alignment effectively located
an unexpected single amino acid polymorphism repre-
senting a novel sequence variant of swine cTnI. Taken
together, our study illustrated the unique power of the
top-down MS strategy in the analysis of protein PTMs
and sequence variants in endogenous protein purified
directly from tissues. Such an unexpected sequence
variant with a single amino acid polymorphism would
be extremely challenging and could have been easily
overlooked using a bottom-up MS approach.
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